Search results for "MOTH"

showing 10 items of 2617 documents

Chemoresistance and chemosensitization in cholangiocarcinoma

2017

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern onco…

0301 basic medicinePharmacologybile ductschemotherapydrug delivery systems0302 clinical medicineChemosensitizationantineoplastic agentsmolecular biologyReceptorhumansreceptor protein-tyrosine kinasesmedia_commonapoptosisgene expression regulationbile duct neoplasmsDrug Resistance Multipletargeted therapiesGene Expression Regulation Neoplasticmultiplebiliary cancer; chemotherapy; liver cancer; multidrug resistance; targeted therapies; antineoplastic agents; apoptosis; bile duct neoplasms; bile ducts; cell survival; cholangiocarcinoma; drug delivery systems; drug resistance multiple; drug resistance; neoplasm; epithelial cells; gene expression regulation neoplastic; genetic therapy; humans; protein kinase inhibitors; receptor protein-tyrosine kinases; signal transduction; treatment outcome; molecular medicine; molecular biology030220 oncology & carcinogenesisHepatocellular carcinomabiliary cancerLiver cancercholangiocarcinomaTyrosine kinasesignal transductionDrugHepatoblastomamedia_common.quotation_subjectcell survivalPharmacological treatmentliver cancer03 medical and health sciencesmultidrug resistancemedicinemolecular medicinedrug resistancebusiness.industrymedicine.diseaseepithelial cellsneoplasticprotein kinase inhibitors030104 developmental biologyDrug Resistance NeoplasmCancer researchtreatment outcomebusinessneoplasmgenetic therapy
researchProduct

Does Pasteurized Donor Human Milk Efficiently Protect Preterm Infants Against Oxidative Stress?

2019

International audience; Pasteurized donor human milk (DHM) is the preferred alternative for infant nutrition when own mother's milk (OMM) is unavailable. Whether DHM is an efficient means for protecting preterm infants from oxidative stress remains unknown. We quantified a panel of oxidative stress biomarkers in urine samples from preterm infants (≤32 weeks of gestation and a birth weight ≤1500 g) receiving ≥80% of feeding volume as either DHM or OMM. The noninvasive in vivo assessment of oxidative stress showed no statistically significant difference between both groups at the time when full enteral nutrition (150 mL/kg body weight) was achieved and until hospital discharge. In addition, t…

0301 basic medicinePhysiology[SDV]Life Sciences [q-bio]Clinical BiochemistryPasteurizationmedicine.disease_causeBiochemistrylaw.inventionpreterm infant03 medical and health sciencesEnteral Nutritionfluids and secretionslawHumansMedicineoxidative stressLongitudinal StudiesProspective StudiesFood scienceMolecular BiologyGeneral Environmental Science2. Zero hungerMilk Human030102 biochemistry & molecular biologyfull enteral feedingbusiness.industryInfant Newbornfood and beveragesbiomarkersInfant nutritionCell BiologyInfant Low Birth Weight3. Good health030104 developmental biologydonor human milk (DHM)own mother's milk (OMM)PasteurizationGeneral Earth and Planetary SciencesFemalebusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionInfant PrematureOxidative stress
researchProduct

Managing adult patients with infectious diseases in emergency departments: international ID-IRI study.

2021

We aimed to explore factors for optimizing antimicrobial treatment in emergency departments. A single-day point prevalence survey was conducted on January 18, 2020, in 53 referral/tertiary hospitals in 22 countries. 1957 (17%) of 11557 patients presenting to EDs had infections. The mean qSOFA score was 0.37 +/- 0.74. Sepsis (qSOFA >= 2) was recorded in 218 (11.1%) patients. The mean qSOFA score was significantly higher in low-middle (1.48 +/- 0.963) compared to upper-middle (0.17 +/- 0.482) and high-income (0.36 +/- 0.714) countries ( P < 0.001). Eight (3.7%) patients with sepsis were treated as outpatients. The most common diagnoses were upper-respiratory (n = 877, 43.3%), lower-respirator…

0301 basic medicinePoint prevalence surveymedicine.medical_specialtyUrologic NeoplasmsReferralinternational ID-IRI study- JOURNAL OF CHEMOTHERAPY 2021 [Erdem H. Hargreaves S. ANKARALI H. ÇAŞKURLU H. Ceviker S. A. Bahar-Kacmaz A. Meric-Koc M. ALTINDİŞ M. Yildiz-Kirazaldi Y. Kizilates F. et al. -Managing adult patients with infectious diseases in emergency departments]medicine.drug_classOrgan Dysfunction Scores030106 microbiologyAntibioticsPractice Patternsemergency ; antibiotic ; elderly ; infection ; sepsis ; treatmentGlobal HealthelderlyCommunicable Diseasestreatment.SepsisHospital03 medical and health sciences0302 clinical medicineantibioticSepsismedicineHumansPharmacology (medical)Practice Patterns Physicians'Developing CountriesRespiratory Tract InfectionsPharmacologyEmergency ServicePhysicians'Adult patientstreatmentbusiness.industryPatient AcuityAntimicrobialmedicine.diseasehumanitiesinfectionDrug UtilizationAnti-Bacterial AgentsInfectious DiseasesOncology030220 oncology & carcinogenesisEmergency medicineEmergencysepsibusinessEmergency Service HospitalJournal of chemotherapy (Florence, Italy)
researchProduct

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors

2017

Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been investigated in ovarian and breast cancer, showing promising efficacy in BRCA-mutated patients. Recently clinical studies of PARP-inhibitors have been extended across different tumor types harboring BRCA-mutations, including also "BRCA-like" sporadic tumors with homologous recombination deficiency (HRD). This review summarizes the biological background underlying PARP-inhibition, reporting the results …

0301 basic medicinePoly ADP ribose polymerasemedicine.medical_treatmentReviewSynthetic lethalityPoly(ADP-ribose) Polymerase Inhibitorsmedicine.disease_causePoly (ADP-Ribose) Polymerase Inhibitorresistance03 medical and health sciences0302 clinical medicineBreast cancerCell Line TumorBRCA1-2AnimalsHumansMedicinePARP inhibitorsBRCA2 ProteinGeneticsMutationChemotherapyBRCA1 Proteinbusiness.industryBRCA1-2; PARP inhibitors; Resistance; Oncologymedicine.diseaseBRCA2 ProteinClinical trialPARP inhibitor030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationCancer researchbusinessOncotarget
researchProduct

Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-M…

2021

Neuroblastoma (NB) is a common malignant solid tumor in children and accounts for 15% of childhood cancer mortality. Amplification of the N-Myc oncogene is a well-established poor prognostic marker in NB patients and strongly correlates with higher tumor aggression and resistance to treatment. New therapies for patients with N-Myc-amplified NB need to be developed. After treating NB cells with BSAO/SPM, the detection of apoptosis was determined after annexin V-FITC labeling and DNA staining with propidium iodide. The mitochondrial membrane potential activity was checked, labeling cells with the probe JC-1 dye. We analyzed, by real-time RT-PCR, the transcript of genes involved in the apoptot…

0301 basic medicinePolyamine; neuroblastoma; apoptosis; microRNA; mitochondria; reactive oxygen species; oncotherapychemistry.chemical_compound0302 clinical medicineAnnexinpolyamineSettore BIO/10 - BiochimicaAntineoplastic Combined Chemotherapy ProtocolsCytotoxic T cellSettore BIO/06 - Anatomia Comparata E CitologiaBiology (General)Membrane Potential Mitochondrialreactive oxygen speciesN-Myc Proto-Oncogene ProteinmicroRNAChemistryCaspase 3apoptosisGeneral MedicineBlotGene Expression Regulation Neoplasticmitochondria030220 oncology & carcinogenesisAmine Oxidase (Copper-Containing)Signal TransductiononcotherapyQH301-705.5Caspase 3apoptosis; microRNA; mitochondria; neuroblastoma; oncotherapy; polyamine; reactive oxygen species.ArticleNO03 medical and health sciencesneuroblastomaNeuroblastomaCell Line TumormedicineAnimalsHumansPropidium iodideRats WistarCell ProliferationOncogeneGene Amplificationmedicine.diseaseapoptosis; microRNA; mitochondria; neuroblastoma; oncotherapy; polyamine; reactive oxygen speciesMolecular biologyMicroRNAs030104 developmental biologyApoptosisSpermineTumor Suppressor Protein p53
researchProduct

Anticancer metal drugs and immunogenic cell death

2016

Conventional chemotherapeutics, but also innovative precision anticancer compounds, are commonly perceived to target primarily the cancer cell compartment. However, recently it was discovered that some of these compounds can also exert immunomodulatory activities which might be exploited to synergistically enhance their anticancer effects. One specific phenomenon of the interplay between chemotherapy and the anticancer immune response is the so-called “immunogenic cell death” (ICD). ICD was discovered based on a vaccination effect exerted by cancer cells dying from pretreatment with certain chemotherapeutics, termed ICD inducers, in syngeneic transplantation mouse models. Interestingly, onl…

0301 basic medicineProgrammed cell deathOrganoplatinum Compoundsmedicine.medical_treatmentAntineoplastic AgentsPharmacologyBiochemistryAntineoplastic AgentInorganic ChemistryMice03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyNeoplasmsmedicineAnimalsHumansEndoplasmic Reticulum StreCisplatinChemotherapyCell DeathAnimalChemistryOrganoplatinum CompoundEndoplasmic Reticulum Stress3. Good healthOxaliplatin030104 developmental biologyAnticancer metal drugSettore CHIM/03 - Chimica Generale E Inorganica030220 oncology & carcinogenesisCancer cellUnfolded protein responseImmunogenic cell deathCisplatinReactive Oxygen SpecieReactive Oxygen SpeciesImmunogenic cell deathHumanmedicine.drugJournal of Inorganic Biochemistry
researchProduct

Insights into apoptotic proteins in chemotherapy: quantification techniques and informing therapy choice.

2018

Cancer is one of the leading causes of morbidity and mortality worldwide. A hallmark of cancer is evasion of apoptosis leading to tumor progression and drug resistance. Biomarker research has become a sign of the times, and proteins involved in apoptosis may be used for clinical diagnostic or prognostic purposes in cancer treatment. The recent progress in proteomic technology has triggered an emerging number of researchers to study the molecular mechanisms that regulate the apoptotic signal transduction pathways in cancer. Areas covered: A PubMed search for 'Proteomics' and 'cancer' and 'chemotherapy' and 'apoptosis' has been conducted for literature until December 2017.The study of apoptot…

0301 basic medicineProteomicsmedicine.medical_treatmentAntineoplastic AgentsApoptosisDrug resistanceProteomicsBioinformaticsBiochemistry03 medical and health sciencesMedicineAnimalsHumansPrecision MedicineMolecular BiologyChemotherapybusiness.industryCancerProteinsPrecision medicinemedicine.diseaseBiomarker (cell)030104 developmental biologyTumor progressionDrug Resistance NeoplasmSignal transductionbusinessExpert review of proteomics
researchProduct

Lethal systemic and brain infection caused by Prototheca zopfii algae in a patient with acute myeloid leukemia

2021

Systemic protothecosis is an exceptionally rare cause of sepsis with few available therapeutic options. Here, we report on a female patient with newly diagnosed acute myeloid leukemia who died after start of chemotherapy due to a severe septic shock caused by a disseminated systemic infection with Prototheca zopfii including encephalitis.

0301 basic medicineProtothecosisMedicine (General)QH301-705.5medicine.medical_treatmentProtothecosis030106 microbiology030231 tropical medicinePrototheca zopfiiCase ReportMicrobiologySepsis03 medical and health sciences0302 clinical medicineR5-920medicineImmunodeficiencyBiology (General)ImmunodeficiencyChemotherapyLeukemiabusiness.industrySeptic shockMyeloid leukemiamedicine.diseaseLeukemiaInfectious DiseasesImmunologyEncephalitisbusinessEncephalitisMedical Mycology Case Reports
researchProduct

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized…

2019

Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on d…

0301 basic medicinePulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDisease-free survivalmedicine.medical_treatmentNeoplasm metastasisAdministration OralVinorelbine03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalneoplasmsEtoposideAgedNeoplasm StagingEtoposideCisplatinbusiness.industryStandard treatmentVinorelbineChemoradiotherapyMiddle AgedPhase IIrespiratory tract diseasesRadiation therapySurvival RateClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantFemalePatient SafetyCisplatinbusinessClinical trial Disease-free survival Etoposide Neoplasm metastasis Non-small cell lung cancer Phase II Vinorelbinemedicine.drug
researchProduct

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysi…

2020

Abstract Objectives To evaluate the effectiveness and safety of nintedanib plus docetaxel in patients with advanced adenocarcinoma non-small cell lung cancer (NSCLC) previously treated with both chemo- and immunotherapy. Materials and methods LUME-BioNIS is a European, prospective, multicenter, non-interventional study of patients with advanced adenocarcinoma NSCLC, who initiated nintedanib plus docetaxel after first-line chemotherapy in routine practice according to the approved nintedanib EU label. The primary objective is to explore whether molecular biomarkers can predict overall survival (OS). Information on clinical or radiologic progression and death, and adverse drug reactions (ADRs…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung Neoplasmsmedicine.medical_treatmentSubgroup analysisPembrolizumabDocetaxelAdenocarcinoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtezolizumabInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerChemotherapybusiness.industrymedicine.disease030104 developmental biologyTreatment OutcomeOncologychemistryDocetaxel030220 oncology & carcinogenesisNintedanibTaxoidsImmunotherapyNivolumabbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct